Page 6 - Eric Elenko News Today

JMP Securities restated their market outperform rating on shares of Karuna Therapeutics (NASDAQ:KRTX – Get Rating) in a report released on Tuesday morning, Benzinga reports. JMP Securities currently has a $323.00 target price on the stock. A number of other equities analysts have also commented on the stock. Mizuho decreased their price objective on shares […]

Wedbush reissued their outperform rating on shares of Karuna Therapeutics (NASDAQ:KRTX – Get Rating) in a research note issued to investors on Tuesday, Benzinga reports. Wedbush also issued estimates for Karuna Therapeutics’ FY2026 earnings at $11.50 EPS and FY2027 earnings at $14.63 EPS. Several other equities analysts have also recently issued reports on KRTX. HC […]

Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Equities research analysts at Wedbush lowered their FY2026 earnings estimates for Karuna Therapeutics in a research report issued to clients and investors on Thursday, March 23rd. Wedbush analyst L. Chico now expects that the company will earn $11.50 per share for the year, down from their prior […]

Arthur M. Cohen & Associates LLC increased its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 50.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,643 shares of the company’s stock after purchasing an additional 548 shares during the […]

Investegate announcements from PureTech Health PLC, PDMR Notification RSU Vesting

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have earned an average rating of “Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Wall Street brokerages forecast that Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) will post ($2.01) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Karuna Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.64) and the lowest estimate coming in at ($2.52). Karuna Therapeutics reported earnings […]

Investegate announcements from PureTech Health PLC, PRTCs Gelesis to Debut on NYSE Today Ticker GLS